TY - JOUR
T1 - Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH consensus criteria
AU - Arai, Sally
AU - Jagasia, Madan
AU - Storer, Barry
AU - Chai, Xiaoyu
AU - Pidala, Joseph
AU - Cutler, Corey
AU - Arora, Mukta
AU - Weisdorf, Daniel J.
AU - Flowers, Mary E D
AU - Martin, Paul J.
AU - Palmer, Jeanne
AU - Jacobsohn, David
AU - Pavletic, Steven Z.
AU - Vogelsang, Georgia B.
AU - Lee, Stephanie J.
PY - 2011/10/13
Y1 - 2011/10/13
N2 - In 2005, the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic GVHD proposed a new scoring system for individual organs and an algorithm for calculating global severity (mild, moderate, severe). The Chronic GVHD Consortium was established to test these new criteria. This report includes the first 298 adult patients enrolled at 5 centers of the Consortium. Patients were assessed every 3-6 months using standardized forms recommended by the Consensus Conference. At the time of study enrollment, global chronic GVHD severity was mild in 10% (n ∇ 32), moderate in 59% (n ∇ 175), and severe in 31% (n ∇ 91). Skin, lung, or eye scores determined the global severity score in the majority of cases, with the other 5 organs determining 16% of the global severity scores. Conventional risk factors predictive for onset of chronic GVHD and nonrelapse mortality in people with chronic GVHD were not associated with NIH global severity scores. Global severity scores at enrollment were associated with nonrelapsemortality (P < .0001) and survival (P < .0001); 2-year overall survival was 62% (severe), 86% (moderate), and 97% (mild). Patients with mild chronic GVHD have a good prognosis, while patients with severe chronic GVHD have a poor prognosis. This study was registered at www.clinicaltrials.gov as no. NCT00637689.
AB - In 2005, the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic GVHD proposed a new scoring system for individual organs and an algorithm for calculating global severity (mild, moderate, severe). The Chronic GVHD Consortium was established to test these new criteria. This report includes the first 298 adult patients enrolled at 5 centers of the Consortium. Patients were assessed every 3-6 months using standardized forms recommended by the Consensus Conference. At the time of study enrollment, global chronic GVHD severity was mild in 10% (n ∇ 32), moderate in 59% (n ∇ 175), and severe in 31% (n ∇ 91). Skin, lung, or eye scores determined the global severity score in the majority of cases, with the other 5 organs determining 16% of the global severity scores. Conventional risk factors predictive for onset of chronic GVHD and nonrelapse mortality in people with chronic GVHD were not associated with NIH global severity scores. Global severity scores at enrollment were associated with nonrelapsemortality (P < .0001) and survival (P < .0001); 2-year overall survival was 62% (severe), 86% (moderate), and 97% (mild). Patients with mild chronic GVHD have a good prognosis, while patients with severe chronic GVHD have a poor prognosis. This study was registered at www.clinicaltrials.gov as no. NCT00637689.
UR - http://www.scopus.com/inward/record.url?scp=80054090049&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80054090049&partnerID=8YFLogxK
U2 - 10.1182/blood-2011-03-344390
DO - 10.1182/blood-2011-03-344390
M3 - Article
C2 - 21791424
AN - SCOPUS:80054090049
SN - 0006-4971
VL - 118
SP - 4242
EP - 4249
JO - Blood
JF - Blood
IS - 15
ER -